Celldex Therapeutics, Inc.

Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results [Press Release]
Business Wire | 18 days 19 hours ago
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008. For the nine months ended September 30, 2009, Celldex reported a net loss of $23.6 million, or $1.49 per share, compared to a net loss of $40.0 million, or $2.92 per ...

Celldex Therapeutics to Present at Merriman Curhan Ford s Investor Summit 2009 [Press Release]
Business Wire | 17 days 13 hours 56 minutes ago
Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at Merriman Curhan Ford’s 6th Annual Investor Summit at the Sofitel Hotel, New York City on Tuesday, November 10, 2009 at 2:40 pm, EST.

Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307 [Press Release]
Business Wire | 24 days 16 hours 57 minutes ago
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer. CDX-1307, the first candidate from the Company’s Precision Targeted Immunotherapy Platform, utilizes monoclonal antibodies to deliver vaccine directly to the patient’s immune system and focuses the immune system against hCG beta (hCG-β), a cancer-associated target believed to play a rol...

Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development [Press Release]
PRNewswire | 82 days 18 hours 28 minutes ago
COPENHAGEN and OSLO, September 1 /PRNewswire-FirstCall/ -- Affitech A/S,

SPARK VCT 2 PLC - Half-yearly Report [Press Release]
PRNewswire | 91 days 58 minutes ago
Financial highlights Per ordinary share (pence) 30.06.09 31.12.08 30.06.08 Net asset value 33.4 36.4 44.3 Dividends Dividend paid (1) - 1.0 1.0 Cumulative dividend (2) 6.9 6.9 6.9 Total return per share (3) SPARK VCT 2 plc 40.3 43.3 51.2

SPARK VCT PLC - Half-yearly Report [Press Release]
PRNewswire | 91 days 59 minutes ago
Financial highlights Per ordinary share (pence) 30.06.09 31.12.08 30.06.08 Net asset value 24.3 26.8 28.7 Dividends Dividend paid (1) - 2.8 2.8 Cumulative dividend (2) 53.7 53.7 53.7 Total return (3) SPARK VCT plc 78.0 80.5 82.4 Return including tax benefits (6) 98.0 100.5 102.4 Total return to former shareholders of: Que...

Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75 [Press Release]
Business Wire | 6 days 17 hours ago
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results [Press Release]
Business Wire | 31 days 10 hours 50 minutes ago
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

Seattle Genetics to Present at Upcoming Investor Conferences [Press Release]
Business Wire | 26 days 10 hours 55 minutes ago
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the "Investors and News" section.